Background: While the addition of androgen deprivation therapy (ADT) to external beam radiation therapy (EBRT) is known to improve overall survival (OS) in Gleason 8-10 (Grade Group 4-5) prostate cancer (PCa), it has been hypothesized that Gleason 9-10 disease, which is less differentiated...
SURVIVAL OUTCOMES IN MEN TREATED WITH ANDROGEN DEPRIVATION THERAPY AS PRIMARY OR SALVAGE PROSTATE CANCER THERAPY: 20 YEAR SINGLE-CENTER EXPERIENCEpriapismsubarachnoid hemorrhagetreatmentischemiccomplicationsphenylephrineblood pressuresickle cell diseaseThe SLIT2 receptor ROBO2 plays a key role in the formation ...
Objective: To explore the long-term survival and prognosis of prostate cancer patients after treated by androgen deprivation therapy. Methods: We conducted a follow-up study of 124 patients with prostate cancer treated by androgen deprivation therapy,and compared the survival times of the patients wit...
23 Background: While the addition of androgen deprivation therapy (ADT) to external beam radiotherapy is known to improve overall survival in Gleason 8-10 prostate cancer, it has been hypothesized that Gleason 9-10 disease, which is less differentiated than Gleason 8 disease, may be less sensiti...
Patients exposed to androgen deprivation therapy (ADT) had a higher hazard of diagnosis of Alzheimer disease compared with those not exposed to ADT. Figure 3. Survival Curve for Dementia View LargeDownload A significantly higher hazard of diagnosis of dementia was observed for patients treated with ...
Complementary traditional Chinese medicine therapy improves survival in patients with metastatic prostate cancer. Medicine (Baltimore). 2016;95:e4475. Article Google Scholar Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–...
Interpretation:The 120-month progression-free survival confirmed the results from the primary analysis. Salvage radiotherapy combined with short-term androgen suppression significantly reduced risk of biochemical or clinical progression and death ... C Carrie,N Magné,P Burban-Provost,... - 《Lancet ...
Androgen deprivation therapy (ADT) is used to delay tumour development and improve survival in patients with prostate cancer. However, several randomized controlled trials and observational studies have suggested that ADT may increase the risk of cardiovascular events. The aim of the study was to eval...
LC, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ (2014) Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Pro...
Although androgen receptor signaling is critical for prostate cancer growth and survival, evidence supporting a favorable risk-benefit ratio of androgen deprivation therapy (ADT) is currently limited to men with high-risk or metastatic disease. This is in part because ADT has been associated with a...